Impact of Early Treatment With High-Dose Intravenous Immunoglobulin on Incidence of Kawasaki Disease Complications in Iranian Children.

Autor: Karimi Yazdi A; Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran., Akbariasbagh P; Department of Pediatrics, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Aghighi Y; Department of Pediatrics, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Raeeskarami SR; Department of Pediatrics, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Toomaj K; Department of Pediatrics, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Heidari S; Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran., Alamdari S; Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran., Sahebi L; Family Health Research Institute, Maternal-Fetal, and Neonatal Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Jazyk: angličtina
Zdroj: Journal of family & reproductive health [J Family Reprod Health] 2021 Dec; Vol. 15 (4), pp. 242-247.
DOI: 10.18502/jfrh.v15i4.7890
Abstrakt: Objective: Kawasaki disease (KD) occurs in five-year-old or younger children. This study aimed to evaluate the impact of high-dose intravenous immunoglobulin plus acetylsalicylic acid therapy on the prevention and treatment of coronary artery lesions and to evaluate the impact of high-dose acetylsalicylic acid (ASA) on the hearing of the patients. Materials and methods: In this retrospective cohort study, 31 patients with KD were followed from January 2012 to December 2015. The clinical, para-clinical, color Doppler echocardiogram and audiometry results were evaluated. Results: Overall, seven cases (22.6%) developed coronary artery aneurysm (CAA) in the acute phase of the disease, of whom only two still had CAA at the end of the treatment (6%). One of the five children with CAA recovery had a delay in the onset of treatment and one of two patients with persistent CAA at the end of treatment was admitted within the first 10 days. There was no evidence-based abnormal liver biochemical test. None of the patients developed sensorineural hearing loss (SNHL) on audiometry tests conducted before and after treatment. Conclusion: Recovery of coronary artery lesions was 71.43% after 28 days of the onset of treatment. The distribution of coronary artery aneurysm was not different in terms of the time of the treatment initiation (P-Value = 0.371). None of the children had a sensorineural hearing loss (SNHL) 48 hours and 4 weeks after treatment.
(Copyright © 2021 Tehran University of Medical Sciences. Published by Tehran University of Medical Sciences.)
Databáze: MEDLINE
Externí odkaz: